TUCSON, Ariz., November 13, 2025 — Critical Path Institute® (C-Path) today announced the appointment of Fatta B. Nahab, M.D., as Industry Co-Director of its Critical Path for Parkinson’s (CPP) consortium. Dr. Nahab is a movement disorders neurologist and biotech executive with deep experience in clinical development, digital measurement, and translational neuroscience. The appointment will further strengthen and align CPP’s multistakeholder community on evidence frameworks that support better endpoints, better trial design, and clearer decision making across therapy development pathways.
Dr. Nahab serves as Vice President of Clinical and Digital Development at Neuron23, where he leads programs that combine clinical insight with data science and digital tools. He previously held academic roles at UC San Diego, focusing on movement disorders care, neuroimaging, and objective measurement. His background spans the clinic, industry, and technology, giving him a singular and practical view of how evidence is generated, validated, and reviewed.
“Dr. Nahab understands the science and the realities of development,” said Diane Stephenson, PhD, Executive Director of CPP. “He knows how to connect biomarkers, clinical endpoints, and digital measures with the perspectives of those with lived experience, and he understands what credible evidence looks like to sponsors and regulators. That experience is exactly what CPP needs as we continue to scale impact for people living with Parkinson’s.”
“I am honored to serve CPP and its members,” said Dr. Nahab. “My focus is to build upon the excellent work of CPP by establishing clear measurement strategies for more efficient trials, working with partners to identify benchmarks that enable comparison of clinical endpoints, and create collaborations that move promising treatments forward. The goal is better evidence, better decisions, and tangible benefits for people with Parkinson’s and their families.”
Dr. Nahab was elected by CPP’s industry members following a competitive process that drew multiple qualified candidates. He is the first leader from a biotechnology company to hold this role at CPP, reflecting deeper engagement with early-stage innovators. While he brings the perspective of a current industry executive, he will represent the needs of all industry members, not a single company, and will work in close partnership with CPP’s academic and patient leaders across the consortium.
A rich pipeline of therapeutics is advancing rapidly to regulatory agencies where precision medicine strategies are key to success in reaching patients in need.
CPP is expanding collaborative work on data integration, biomarkers, and digital health, including efforts to align digital measures with outcomes that matter to those with lived experience. The program is also advancing initiatives to ensure evidence reflects the lived experience of women with Parkinson’s and other underrepresented groups. Dr. Nahab’s cross-sector background supports these priorities and strengthens CPP’s ability to convene credible, patient-centered science that accelerates progress worldwide.
Working alongside CPP’s Academic Co-Director, the steering committee, and workstream leads, Dr. Nahab will help prioritize projects that reduce uncertainty in decision making, from fit-for-purpose biomarkers to analysis-ready shared datasets. He will support member companies in defining common problems that are larger than any single sponsor and in mapping practical paths to regulatory acceptance. Priorities include interoperability across datasets, clarity on endpoint performance, privacy-preserving analytical methods, and transparent communication of results to build trust across stakeholders.
The appointment takes effect immediately.
About Critical Path Institute
Founded in 2005, as a public-private partnership in response to the FDA’s Critical Path Initiative, Critical Path Institute® (C-Path) celebrates its 20th anniversary as a vital, independent, nonprofit. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
Media Contacts:
Roxan Triolo Olivas
C-Path
520.954.1634
rolivas@c-path.org
Kissy Black
C-Path
615.310.1894
kblack@c-path.org
